Enveric Biosciences Inc. (ENVB): Price and Financial Metrics
ENVB Price/Volume Stats
Current price | $1.00 | 52-week high | $6.98 |
Prev. close | $1.02 | 52-week low | $0.65 |
Day low | $1.00 | Volume | 268,300 |
Day high | $1.04 | Avg. volume | 4,456,572 |
50-day MA | $1.03 | Dividend yield | N/A |
200-day MA | $1.89 | Market Cap | 5.40M |
ENVB Stock Price Chart Interactive Chart >
Enveric Biosciences Inc. (ENVB) Company Bio
Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from ... More
Latest ENVB News From Around the Web
Below are the latest news stories about ENVERIC BIOSCIENCES INC that investors may wish to consider to help them evaluate ENVB as an investment opportunity.
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 SeriesCAMBRIDGE, Mass., December 28, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series. EB-003 was selected based on data analyses suggesting the molecule’s potential to be a first-in-class appr |
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373CAMBRIDGE, Mass., December 27, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results. |
Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"CAMBRIDGE, Mass., December 20, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, announced the company will participate in Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco. |
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived CompoundsCAMBRIDGE, Mass., December 05, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has identified three novel compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing |
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin DerivativesCAMBRIDGE, Mass., November 29, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatme |
ENVB Price Returns
1-mo | 20.34% |
3-mo | -23.08% |
6-mo | -57.98% |
1-year | -39.39% |
3-year | -99.33% |
5-year | N/A |
YTD | -23.08% |
2023 | -37.50% |
2022 | -95.53% |
2021 | -78.17% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...